RxDoctor Payments Data

Francisco Jaume Boscio

Cardiovascular Disease · Aguadilla, PRNPI 1114908704

Payments from drug & device makers

$579in general payments, 2019–2025

Across 20 payments — averaging $28.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$203
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$97
  • Johnson & Johnson$73
  • PBG Puerto Rico LLC$57
  • Medtronic$54
  • Pfizer Pharmaceuticals LLC$34
  • plus $60 from 3 others

What the payments were for

  • Food & beverage$579100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific4$203
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)2$97
Johnson & Johnson3$73
PBG Puerto Rico LLC3$57
Medtronic3$54
Pfizer Pharmaceuticals LLC2$34
AstraZeneca1$23
Boehringer Ingelheim1$19
E.r. Squibb & Sons, L.L.C.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$579 in reported general payments places this provider in the 20th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$19,748
Medicare patients
77
Services billed
240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban214$141,743
XareltoRivaroxaban79$52,001
FarxigaDapagliflozin Propanediol68$41,464
EntrestoSacubitril/Valsartan43$30,325
Candesartan Cilexetil100$9,673
Doxazosin Mesylate266$5,038
Metoprolol Succinate365$4,221
Carvedilol ErCarvedilol Phosphate17$3,682
Losartan Potassium391$3,294
Irbesartan180$3,264
Hydralazine Hcl438$3,132
Carvedilol482$2,766
Amlodipine Besylate536$2,437
Rosuvastatin Calcium306$2,369
Diltiazem 24hr Er (Cd)Diltiazem Hcl72$2,146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$73$52,00179 claims
AstraZenecaFarxiga$23$41,46468 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Aguadilla

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →